Bucindolol: new hopes from reviewing past data.
β-Adrenoceptor antagonists or β-blockers are a cornerstone of therapy in chronic heart failure (CHF). Bucindolol hydrochloride is a fourth-generation β-blocker in development for the treatment of CHF. Two trials have been conducted to evaluate its use in CHF, and a third is under way to investigate bucindolol for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. This review aims to summarize the history, pharmacology and clinical trials of bucindolol.
Duke University Medical Center, Durham, NC, USA. Mona.Fiuzat@Duke.edu
M
M
Fiuzat
C M
CM
O'Connor
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011412:Propanolamines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C024307:bucindolol